A Phase 2 interventional study of GLK-321 low dose BID and GLK-321 mid dose BID in Demodex Blepharitis, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Blepharitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Blepharitis · United States.
Among the 39 studies in Blepharitis with a site in United States, this one is the 7th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 in phase 2, and was the 36th registered.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
Browse Blepharitis studies →5 of the 39 studies in Blepharitis with a site in United States are open now. Recruiting first, the newest first:
Brent Kramer · Sites in United States
Ages 18+
Olympic Ophthalmics, Inc. · Sites in United States
Ages 18+
University of Notre Dame · Sites in United States
Ages 18+ · Healthy volunteers
Brent Kramer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Blepharitis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 5 · Phase 4 11
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 60 across 65 interventional studies indexed under Blepharitis.
Median enrollment 60 across the 37 interventional studies, 330 across the 2 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 39 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Glaukos Corporation has 1 study filed under Blepharitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Blepharitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07856680Brent KramerClinical Lid Eradication of Antifungal-Responsive FUNGUS Study | 2027-03 |
| NCT07869498Brent KramerOcular Dysbiosis in Eyelid Disease | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 39 studies in Blepharitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose of GLK-321 administered twice daily (BID) to both eyes
Drug: GLK-321 low dose BID
Mid dose of GLK-321 administered twice daily (BID) to both eyes
Drug: GLK-321 mid dose BID
High dose of GLK-321 administered twice daily (BID) to both eyes
Drug: GLK-321 high dose BID
High dose of GLK-321 administered once daily (QD) to both eyes
Drug: GLK-321 high dose QD
Placebo administered twice daily (BID) to both eyes
Drug: Placebo BID
Twice daily administration of low dose GLK-321 to both eyes
Twice daily administration of mid dose GLK-321 to both eyes
Twice daily administration of high dose GLK-321 to both eyes
Once daily administration of high dose GLK-321 to both eyes
Twice daily administration of placebo to both eyes
Percentage of study eyes with elimination of collarettes
Percentage of study eyes that had eyelash collarettes due to Demodex blepharitis at the onset of treatment who demonstrate absence of collarettes after 6 weeks of treatment
Time frame: 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Sep 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.